← Eichor
Condition: Fallopian Tube Endometrioid Tumor Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Fallopian Tube Endometrioid Tumor

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
Phase 3 · 53 location(s) · Swiss GO Trial Group · NCT04111978Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Beva
Phase 3 · 32 location(s) · Genelux Corporation · NCT05281471Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
Phase 2 · 2 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT06617923Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Re
Phase 2 · 2 location(s) · Roswell Park Cancer Institute · NCT05231122CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Phase 2 · 66 location(s) · TORL Biotherapeutics, LLC · NCT06690775Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal
Phase 3 · 19 location(s) · M.D. Anderson Cancer Center · NCT04575935Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of
EARLY_Phase 1 · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT05415709Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade En
Phase 2 · 1 location(s) · University College, London · NCT05080556A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologo
Phase 2 · 10 location(s) · Oncoinvent Solutions AS · NCT06504147APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurr
Phase 2 · 1 location(s) · Roswell Park Cancer Institute · NCT04919629Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Phase 3 · 676 location(s) · NRG Oncology · NCT06580314Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fa
Phase 2 · 3 location(s) · Mayo Clinic · NCT06639074Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian
Phase 1 · 2 location(s) · University of Colorado, Denver · NCT06856499Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Phase 1/Phase 2 · 3 location(s) · Mayo Clinic · NCT05920798OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy
NA · 7 location(s) · Swiss GO Trial Group · NCT06466382
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.